Does kidney disease cause hypertension?

Current Hypertension Reports

Volumn 15, Issue 2, 2013, Pages 89-94

  Peixoto, Aldo J ^a,b,d   Orias, Marcelo ^c   Desir, Gary V ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Sanatorio Allende   (Argentina)

^d Medical Service 111   (United States)

Author keywords

Albuminuria; Chronic kidney disease; CKD; Hematuria; Hypertension; Kidney failure; Polycystic kidney disease; Proteinuria; Renal function

Indexed keywords

AMILORIDE; EPITHELIAL SODIUM CHANNEL; PLASMIN; SPIRONOLACTONE; TRIAMTERENE;

CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; EDEMA; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR FLUID; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HEMATURIA; HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY CYST; KIDNEY DYSFUNCTION; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PROTEINURIA; REVIEW; SODIUM RETENTION;

GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; KIDNEY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84879606246     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0327-6     Document Type: Review

References (57)

1. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens. 1988;1:335-47.
2. Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med. 2003;348:101-8.
3. Rao MV, Qiu Y, Wang C, Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008;51:S30-7.
4. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Chapter 1: definition and classification of CKD. Kidney Int Suppl. 2013;3:19-62.
5. Bidani AK, Mitchell KD, Schwartz MM, Navar LG, Lewis EJ. Absence of glomerular injury or nephron loss in a normotensive rat remnant kidney model. Kidney Int. 1990;38:28-38.
6. Adams LG, Polzin DJ, Osborne CA, O'Brien TD, Hostetter TH. Influence of dietary protein/calorie intake on renal morphology and function in cats with 5/6 nephrectomy. Lab Investig. 1994;70:347-57.
7. Bourgoignie JJ, Gavellas G, Hwang KH, Disbrow MR, Sabnis SG, Antonovych TT. Renal function of baboons (Papio hamadryas) with a remnant kidney, and impact of different protein diets. Kidney Int Suppl. 1989;27:S86-90.
8. Robertson JL, Goldschmidt M, Kronfeld DS, Tomaszewski JE, Hill GS, Bovee KC. Long-term renal responses to high dietary protein in dogs with 75 % nephrectomy. Kidney Int. 1986;29:511-9.
9. Houck CR. Effect of hydration and dehydration on hypertension in the chronic bilaterally nephrectomized dog. Am J Physiol. 1954;176:183-9.
10. Kren S, Hostetter TH. The course of the remnant kidney model in mice. Kidney Int. 1999;56:333-7.
11. Griffin KA, Picken M, Bidani AK. Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol. 1994;4:2023-31.
12. Ibrahim HN, Hostetter TH. The renin-aldosterone axis in two models of reduced renal mass in the rat. J Am Soc Nephrol. 1998;9:72-6.
13. Ylitalo P, Hepp R, Mohring J, Gross F. Effects of varying sodium intake on blood pressure and renin-angiotensin system in subtotally nephrectomized rats. J Lab Clin Med. 1976;88:807-16.
14. Merrill JP, Giordano C, Heetderks DR. The role of the kidney in human hypertension. I. Failure of hypertension to develop in the renoprival subject. Am J Med. 1961;31:931-40.
15. Santos SF, Peixoto AJ. Sodium balance in maintenance hemodialysis. Semin Dial. 2010;23:549-55.
16. Chan CT, Harvey PJ, Picton P, Pierratos A, Miller JA, Floras JS. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension. 2003;42:925-31.
17. Katzarski KS, Charra B, Luik AJ, Nisell J, Divino Filho JC, Leypoldt JK, et al. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant. 1999;14:369-75.
18. Boudville N, Prasad GV, Knoll G, Muirhead N, Thiessen-Philbrook H, Yang RC, et al. Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med. 2006;145:185-96.
19. • Rodriguez-Gomez I, Wangensteen R, Perez-Abud R, Quesada A, Del Moral RG, Osuna A, et al. Long-term consequences of uninephrectomy in male and female rats. Hypertension. 2012;60:1458-63. Uninephrectomy results in salt-sensitive hypertension, especially in female animals.
20. Blumenfeld JD, Liu F, Laragh JH. Primary and secondary hypertension. In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu AS, Brenner BM, editors. Brenner and Rector's the kidney. 9th ed. Philadelphia: Elsevier Saunders; 2012. p. 1670-751.
21. • Chapman AB, Stepniakowski K, Rahbari-Oskoui F. Hypertension in autosomal dominant polycystic kidney disease. Adv Chron Kidney Dis. 2010;17:153-63. Valuable review of mechanisms of hypertension in polycycstic kidney disease.
22. Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2009;20:1888-93.
23. Morel N, Vandenberg G, Ahrabi AK, Caron N, Desjardins F, Balligand JL, et al. PKD1 haploinsufficiency is associated with altered vascular reactivity and abnormal calcium signaling in the mouse aorta. Pflugers Arch. 2009;457:845-56.
24. •• Brookes ZL, Ruff LJ, Upadhyay VS, Huang L, Prasad S, Solanky T, et al. Pkd2 mesenteric vessels exhibit a primary defect in endothelial dependent vasodilatation restored by rosiglitazone. Am J Physiol Heart Circ Physiol. 2012. Polycystin 2 haploinsufficiency results in endothelial dysfunction that can be ameliorated by rosiglitazone. This is a paper that not only focuses on mechanisms but also has potential treatment implications.
25. Chin HJ, Ro H, Lee HJ, Na KY, Chae DW. The clinical significances of simple renal cyst: is it related to hypertension or renal dysfunction? Kidney Int. 2006;70:1468-73.
26. Luscher TF, Wanner C, Siegenthaler W, Vetter W. Simple renal cyst and hypertension: cause or coincidence? Clin Nephrol. 1986;26:91-5.
27. Melo NC, Mundim JS, Costalonga EC, Lucon AM, Santello JL, Praxedes JN. Three cases of hypertension and renal arteriovenous fistula with a de novo fistula. Arq Bras Cardiol. 2009;92:e36-e38.
28. Smith MC, Lazar A, Rahman M. Hypertension associated with renal parenchymal disease. In: Schrier RW, editor. Diseases of the kidney and urinary tract. 8th ed. Philadelphia: Lippincott, Williams and Wilkins; 2007. p. 1238-64.
29. Sterns RH, Rabinowitz R, Segal AJ, Spitzer RM. 'Page kidney'. Hypertension caused by chronic subcapsular hematoma. Arch Intern Med. 1985;145:169-71.
30. Fidan K, Kandur Y, Buyukkaragoz B, Akdemir UO, Soylemezoglu O. Hypertension in pediatric patients with renal scarring in association with vesicoureteral reflux. Urology. 2012.
31. • Chughtai HL, Morgan TM, Rocco M, Stacey B, Brinkley TE, Ding J, et al. Renal sinus fat and poor blood pressure control in middle-aged and elderly individuals at risk for cardiovascular events. Hypertension. 2010;56:901-6. Fat accumulation in the renal sinuses is associated with increased prevalent hypertension and lower GFR.
32. • Foster MC, Hwang SJ, Porter SA, Massaro JM, Hoffmann U, Fox CS. Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study. Hypertension. 2011;58:784-90. Fat accumulation in the renal sinuses is associated with increased prevalent hypertension and lower GFR.
33. Burnett Jr JC, Knox FG. Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol. 1980;238:F279-82.
34. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int. 1986;29:1215-23.
35. • Agarwal R, Light RP. GFR, proteinuria and circadian blood pressure. Nephrol Dial Transplant. 2009;24:2400-6. Low GFR and proteinuria have separate effects on BP levels and circadian BP rhythm. Proteinuria is associated with the higher BP levels and more prominent blunting of the circadian rhythm than low GFR. The presence of both is synergistic.
36. •• Svenningsen P, Friis UG, Versland JB, Buhl KB, Frederiksen BM, Andersen H, et al. Mechanisms of renal NaCl retention in proteinuric disease. Acta Physiol (Oxf). 2012. Up-to-date review on the recent advances related to the role of plasmin in stimulating ENaC activity in proteinuric patients (including the important original data described in references 37 and 38).
37. •• Svenningsen P, Bistrup C, Friis UG, Bertog M, Haerteis S, Krueger B, et al. Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol. 2009;20:299-310. As above.
38. •• Buhl KB, Friis UG, Svenningsen P, Gulaveerasingam A, Ovesen P, Frederiksen-Moller B, et al. Urinary plasmin activates collecting duct ENaC current in preeclampsia. Hypertension. 2012;60:1346-51. As above.
39. Nieuwhof C, Doorenbos C, Grave W, de Heer F, de Leeuw P, Zeppenfeldt E, et al. A prospective study of the natural history of idiopathic non-proteinuric hematuria. Kidney Int. 1996;49:222-5.
40. Szeto CC, Mac-Moune Lai F, Kwan BC, Leung CB, Choi PC, Pang WF, et al. The width of the basement membrane does not influence clinical presentation or outcome of thin glomerular basement membrane disease with persistent hematuria. Kidney Int. 2010;78:1041-6.
41. van Paassen P, van Breda Vriesman PJ, van Rie H, Tervaert JW. Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry. Kidney Int. 2004;66:909-13.
42. Frasca GM, Onetti-Muda A, Mari F, Longo I, Scala E, Pescucci C, et al. Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis - a collaborative study of the Italian Renal Immunopathology Group. Nephrol Dial Transplant. 2005;20:545-51.
43. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med. 2002;346:913-23.
44. Rodriguez-Iturbe B, Johnson RJ. The role of renal microvascular disease and interstitial inflammation in salt-sensitive hypertension. Hypertens Res. 2010;33:975-80.
45. Brantsma AH, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. Urinary albumin excretion as a predictor of the development of hypertension in the general population. J Am Soc Nephrol. 2006;17:331-5.
46. Forman JP, Fisher ND, Schopick EL, Curhan GC. Higher levels of albuminuria within the normal range predict incident hypertension. J Am Soc Nephrol. 2008;19:1983-8.
47. Jessani S, Levey AS, Chaturvedi N, Jafar TH. High normal levels of albuminuria and risk of hypertension in Indo-Asian population. Nephrol Dial Transplant. 2012;27 Suppl 3:iii58-64.
48. Palatini P, Mormino P, Mos L, Mazzer A, Dorigatti F, Zanata G, et al. Microalbuminuria, renal function and development of sustained hypertension: a longitudinal study in the early stage of hypertension. J Hypertens. 2005;23:175-82.
49. Wang TJ, Evans JC, Meigs JB, Rifai N, Fox CS, D'Agostino RB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation. 2005;111:1370-6.
50. Wang TJ, Gona P, Larson MG, Levy D, Benjamin EJ, Tofler GH, et al. Multiple biomarkers and the risk of incident hypertension. Hypertension. 2007;49:432-8.
51. Glassock RJ. Is the presence of microalbuminuria a relevant marker of kidney disease? Curr Hypertens Rep. 2010;12:364-8.
52. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol. 2007;2:581-90.
53. Nicholl DD, Hemmelgarn BR, Turin TC, MacRae JM, Muruve DA, Sola DY, et al. Increased urinary protein excretion in the "normal" range is associated with increased renin-angiotensin system activity. Am J Physiol Ren Physiol. 2012;302:F526-32.
54. Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM. Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension. 1994;23:195-9.
55. Warnock DG. Liddle syndrome: genetics and mechanisms of Na + channel defects. Am J Med Sci. 2001;322:302-7.
56. Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, Zhao Q, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005;46:481-7.
57. Hoefnagels WH, Drayer JI, Smals AG, Kloppenborg PW. Spironolactone and amiloride in hypertensive patients with and without aldosterone excess. Clin Pharmacol Ther. 1980;27:317-23.